Amylyx Pharmaceuticals Inc (AMLX) - News Archive

: Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX), a key player in the pharmaceutical industry, has announced a substantial undertaking in its financial strategy through the initiation of a public offering. This communiqué...

Amylyx Pharmaceuticals has released promising data regarding AMX0035, a therapeutic combination of sodium phenylbutyrate (PB) and taurursodiol (TURSO), for the treatment of Alzheimer s disease (AD). The results of explo...

Amylyx Pharmaceuticals Inc Shares Face Significant Challenges Amidst Industry VolatilityIn recent times, Amylyx Pharmaceuticals Inc has faced a series of difficulties, leading to a significant dip in the company s share...

Amylyx Pharmaceuticals Inc Struggles in a Challenging YearAmylyx Pharmaceuticals Inc has faced a difficult year, with its shares lagging behind the overall market performance. Year to date, the company s shares have dro...

On 2024-06-23, a breaking news story from Reuters highlighted the concerns of Chinese domestic investors, as they withdraw cash from the mainland and shift their focus towards Hong Kong in the wake of a depreciating yua...

Amylyx Pharmaceuticals Inc. Targets New Pathways in Metabolic Disease After ALS SetbackIn a notable strategic pivot, Amylyx Pharmaceuticals Inc. is delving into the realm of metabolic diseases by acquiring a clinical-st...

Neurodegenerative diseases, such as Alzheimer s disease, Parkinson s disease, and amyotrophic lateral sclerosis (ALS), have devastating impacts on patients and their families. Recognizing the urgent need for effective t...

is closely monitoring the proceedings of a securities class action involving Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX). Amylyx Pharmaceuticals Inc. investors who incurred losses in excess of $100,000 are greatly encou...

Holzer & Holzer, LLC, a renowned investor rights firm, is reminding shareholders of the upcoming April 9, 2024, lead plaintiff deadline in the class action lawsuit against Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX). Th...

Amylyx Pharmaceuticals Phase 3 Trial of AMX0035 in ALS Fails to Meet Primary EndpointAmylyx Pharmaceuticals, a biopharmaceutical company based in Cambridge, Massachusetts, recently announced the topline results from its...

aims to provide the latest scientific research, industry developments, and regulatory updates in the field of pharmaceuticals. In line with our commitment to providing valuable insights to our readers, this article shed...